NPPA Fixes Retail Prices of 37 Drug Formulations Including Atorvastatin, Ezetimibe, Telmisartan, Details
New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed retail prices of 37 formulations under the Drugs (Prices Control) Order, 2013.
The authority has fixed the retail prices based on the decision of the 141st Authority meeting dated 23.12.2025.
The list of formulations that are price fixed includes Pure and Cure Healthcare/Eris Lifesciences' Atorvastatin and Ezetimibe Tablets, Akums Drugs & Pharmaceuticals/Cipla's Bilastine and Montelukast Tablets, Windlas Biotech/Dr. Reddy’s Laboratories' Bisoprolol Fumarate and Telmisartan Tablets, Akums Drugs & Pharmaceuticals/Mankind Pharma's Myo-Inositol and Metformin Hydrochloride (SR) Tablets, and others.
Further, the retail price of Glenmark Pharmaceuticals' Glycopyrronium, Formoterol Fumarate, Budesonide Inhalation Suspension and Eris Lifesciences' Sitagliptin, Gliclazide (SR), Metformin Hydrochloride (SR) Tablets has been fixed.
This came in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Aceclofenac & Paracetamol Tablets | Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg | 1 Tablet | M/s Shiva Biogenetic Pharmaceuticals Pvt. Ltd./ M/s Softdeal Pharmaceutical Pvt. Ltd. | 5.46 |
2 | Albendazole & Ivermectin suspension | Each 5ml contains: Albendazole IP 200 mg Ivermectin IP 3 mg | 1 ml | M/s Yacca Lifesciences Pvt. Ltd./ M/s Wockhardt Ltd. | 1.39 |
3 | Atorvastatin & Ezetimibe Tablets | Each Film Coated Tablet Contains: Atorvastatin Calcium IP Eq. to Atorvastatin 80mg Ezetimibe IP 10mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Eris Lifesciences Ltd. | 36.12 |
4 | Bilastine & Montelukast Tablets | Each film coated bilayered tablet contains: Bilastine IP 40 mg Montelukast Sodium IP eq. to Montelukast10mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Cipla Ltd. | 22.78 |
5 | Bisoprolol fumarate & Telmisartan Tablets | Each film coated Bi-layered tablet contains: Bisoprolol fumarate IP 2.5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 10.50 |
6 | Bisoprolol fumarate & Telmisartan Tablets | Each film coated Bi-layered tablet contains: Bisoprolol fumarate IP 5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Mascot Health series Pvt. Ltd./ M/s Primus Remedies Pvt. Ltd. | 12.00 |
7 | Bisoprolol fumarate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol fumarate IP 2.5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Dr. Reddy’s Laboratories Ltd. | 10.00 |
8 | Bisoprolol fumarate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol fumarate IP 5 mg Telmisartan IP 40 mg | 1 Tablet | M/s Windlas Biotech Ltd./ M/s Dr. Reddy’s Laboratories Ltd. | 12.18 |
9 | Calcium Aspartate, Calcium Orotate, Calcitriol, Minerals & vitamins tablets | Each Film Coated Tablet Contains: Calcium Aspartate 500 mg Calcium Orotate 500 mg Calcitriol IP 0.25 mcg Zinc (As Zinc Sulphate | 1 Tablet | M/s Troikaa Pharmaceuticals Ltd. | 17.78 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Monohydrate) IP 7.5 mg Magnesium Hydroxide IP 50 mg Hydroxocobalamin IP 100 mcg Folic Acid IP 1.5 mg | |||||
10 | Calcium, Vitamin D3, Methyl cobalamin, L- Methyl folate Calcium & Pyridoxal-5- Phosphate Tablets | Each film coated tablet contains: Calcium Carbonate IP 1250 mg Eq. to Elemental Calcium 500 mg Vitamin D3 IP 2000 IU Methyl cobalamin IP 1500 mcg L-Methyl folate Calcium 1 mg Pyridoxal-5- Phosphate 20 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. M/s Pharmed Ltd. | 19.24 |
11 | Cholecalciferol (Vitamin D3) Oral Solution | Each 5 ml contains: Cholecalciferol IP (In Nano Droplet form) 60000 IU | 1 ml | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Troikaa Pharmaceuticals Ltd. | 15.60 |
12 | Dextromethorphan Hydrobromide, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup | Each 5 ml contains: Dextromethorphan Hydrobromide IP 15 mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s East African (I) Overseas / M/s SRK Puremed LLP | 0.98 |
13 | Levocetirizine Dihydrochloride & Montelukast Sodium Syrup | Each 5ml contains: Levocetirizine Dihydrochloride IP 2.5 mg Montelukast Sodium IP eq. to Montelukast 4 Mg | 1 ml | M/s Tirupati Medicare Ltd./ M/s German Remedies Pharmaceuticals Pvt. Ltd. | 1.67 |
14 | Mefenamic acid & Paracetamol oral suspension | Each 5 ml contains: Mefenamic acid IP 50 mg Paracetamol IP 125 mg | 1 ml | M/s East African (I) Overseas / M/s SRK Puremed LLP | 0.77 |
15 | Mefenamic acid & Paracetamol oral suspension | Each 5 ml contains: Mefenamic acid IP 100 mg Paracetamol IP 250 mg | 1 ml | M/s East African (I) Overseas / M/s SRK Puremed LLP | 0.92 |
16 | Mefenamic acid & Paracetamol Tablets | Each uncoated tablet contains: Mefenamic Acid IP 500mg Paracetamol IP 325mg | 1 Tablet | M/s East African (I) Overseas / M/s SRK Puremed LLP | 3.91 |
17 | Mefenamic Acid & Paracetamol Suspension | Each 5 ml contains: Mefenamic Acid IP 100 mg Paracetamol IP 250 mg | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Glensmith Labs Pvt. Ltd. | 0.90 |
18 | Mefenamic Acid & Paracetamol Suspension | Each 5 ml contains: Mefenamic Acid IP 100 mg Paracetamol IP 250 mg | 1 ml | M/s Skymap Pharmaceuticals Pvt. Ltd./ M/s Jagsonpal Pharmaceuticals Ltd. | 0.90 |
19 | Meropenem & Sulbactam for Injection | Each vial contains: Sulbactam Sodium (Sterile) IP Equivalent to Sulbactam 500 mg Meropenem (Sterile) IP Equivalent to Anhydrous Meropenem 1000 mg Sodium Carbonate (As buffer) | 1 Vial | M/s Gufic Biosciences Ltd./ M/s Intas Pharmaceuticals Ltd. | 1500.00 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
(Sterile) IP Equivalent to Sodium 90.2 mg | |||||
20 | Myo-Inositol & Metformin Hydrochloride (SR) Tablets | Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. M/s Mankind Pharma Ltd. | 23.59 |
21 | Myo-Inositol & Metformin Hydrochloride (SR) Tablets | Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. M/s Emcure Pharmaceuticals Ltd. | 23.59 |
22 | Myo-Inositol & Metformin Hydrochloride (SR) Tablets | Each Film Coated Bilayered Tablet Contains: Myo-Inositol IP 600 mg Metformin Hydrochloride IP 500 mg (As sustained release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. M/s Torrent Pharmaceuticals Ltd. | 23.59 |
23 | Moxifloxacin Hydrochloride & Ketorolac Tromethamine Ophthalmic solution | Composition: Moxifloxacin Hydrochloride IP Eq. to Moxifloxacin 0.5% w/v Ketorolac Tromethamine IP 0.5 % w/v Preservative: Benzalkonium Chloride solution IP 0.01% w/v | 1 ml | M/s East African (I) Overseas / M/s Torrent Pharmaceuticals Ltd. | 15.00 |
24 | Multiple Electrolytes and 5% Dextrose Injection Type-I USP | Each 100 mL contains: Sodium Chloride IP 526 mg Sodium Gluconate USP 502 mg Sodium Acetate Trihydrate IP 368 mg Potassium Chloride IP 37 mg Magnesium Chloride Hexahydrate IP 30 mg Dextrose Monohydrate IP 5000 mg | 1 pack of 500 mL | M/s Otsuka Pharmaceutical India Pvt. Ltd. | 133.97 |
25 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Tablets | Each uncoated tablet contains: Paracetamol IP 500 mg Phenylephrine Hydrochloride IP 10 mg Chlorpheniramine Maleate IP 2 mg | 1 Tablet | M/s East African (I) Overseas / M/s Intas Pharmaceuticals Ltd. | 5.34 |
26 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Suspension | Each 5 ml contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s Mascot Health Series Pvt. Ltd./ M/s Stedman Pharmaceuticals Pvt. Ltd. | 1.36 |
27 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Suspension | Each 5 ml contains: Paracetamol IP 125 mg Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s Mascot Health Series Pvt. Ltd./ M/s Macleods Pharmaceuticals Ltd. | 1.31 |
28 | Paracetamol, Phenylephrine Hydrochloride & Chlorpheniramine Maleate Suspension | Each 5 ml contains: Paracetamol IP 250 mg Phenylephrine Hydrochloride IP 5mg | 1 ml | M/s Mascot Health Series Pvt. Ltd./ M/s Macleods Pharmaceuticals Ltd. | 1.36 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Chlorpheniramine Maleate IP 2mg | |||||
29 | Paroxetine (CR) & Clonazepam Capsules | Each hard gelatin capsule contains: Paroxetine Hydrochloride Hemihydrate IP Eq. to Paroxetine 12.5 mg (as enteric coated controlled release tablet) Clonazepam IP 0.25 mg (as uncoated Clonazepam Tablets IP) | 1 Capsule | M/s Windlas Biotech Ltd./ M/s Ipca Laboratories Ltd. | 15.53 |
30 | Phenylephrine Hydrochloride & Chlorpheniramine Maleate Syrup | Each 5ml contains: Phenylephrine Hydrochloride IP 5 mg Chlorpheniramine Maleate IP 2 mg | 1 ml | M/s East African (I) Overseas/ M/s SRK Puremed LLP | 0.95 |
31 | Povidone-Iodine & Metronidazole Ointment | Composition: Povidone-Iodine IP 5 % w/w (0.5 % w/w available Iodine) Metronidazole IP 1 % w/w | 1 GM | M/s Stedman Pharmaceuticals Pvt. Ltd. | 4.00 |
32 | Tropicamide, Phenylephrine Hydrochloride & Lidocaine Hydrochloride Injection (Intra cameral Injection) | Each ml contains: Tropicamide IP 0.2 mg Phenylephrine Hydrochloride IP 3.1 mg Lidocaine Hydrochloride IP 10 mg | 1 ml AMPOULE | M/s Samarth Life Sciences Pvt. Ltd. | 124.28 |
33 | Vitamin D3 nano syrup | Each 5ml Contains: Cholecalciferol IP 60,000 IU (in Nano Droplet Form) | 1 ml | M/s Unicure India Ltd./ M/s Obsurge Biotech Ltd. | 15.60 |
34 | Dapagliflozin and Telmisartan Tablets | Each film coated tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10 mg Telmisartan IP 40 mg | 1 Tablet | M/s Exemed Pharmaceuticals/ M/s Glenmark Pharmaceuticals Ltd. | 18.27 |
35 | Glycopyrronium, Formoterol Fumarate, Budesonide Inhalation Suspension | Each Smartule contains: Glycopyrrolate IP Eq. to Glycopyrronium 25 mcg Formoterol Fumarate Dihydrate IP Eq. to Formoterol Fumarate 20 mcg Budesonide IP 500 mcg | 1 ml | M/s Glenmark Pharmaceuticals Ltd. | 49.00 |
36 | Sitagliptin, Gliclazide (SR), Metformin Hydrochloride (SR) Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100 mg Gliclazide IP 60 mg (As sustained release) Metformin Hydrochloride IP 500mg (As sustained release) | 1 Tablet | M/s Eris Lifesciences Ltd. | 22.91 |
37 | Paracetamol, Chlorpheniramine Maleate Tablets | Each Uncoated Tablet Contains: Paracetamol IP 325 mg Chlorpheniramine Maleate IP 2 mg | 1 Tablet | M/s Indoco Remedies Ltd. | 6.80 |
The notification further added:
(a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the official notice, click the link below:
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.